Blood Pressure, Physical Activity
Conditions
Keywords
Pilates, Blood Pressure, Postmenopausal women
Brief summary
This project aims to verify the chronic effect of Mat Pilates exercise on climacteric symptoms, ambulatory blood pressure responses, lipid and glucose profile and pro and anti-inflammatory and antioxidant markers in postmenopausal normotensive and hypertensive women. All volunteers received the same intervention.
Detailed description
The Pilates program was performed three times a week for 12 weeks. Initially a familiarization was made regarding the principles of the method. All volunteers underwent 24-hour blood pressure assessment using ambulatory blood pressure measurement (ABPM) and venous blood samples were collected from fasting, saliva and questionnaires before and after the Pilates training period.
Interventions
OTHERHypertensive group
Pilates 12-week training on the ground, often 3 times a week for 50 minutes of prescribed method exercises.
OTHERNormotensive group
Pilates 12-week training on the ground, often 3 times a week for 50 minutes of prescribed method exercises.
Sponsors
Federal University of Uberlandia
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
* Group 1 - Hypertensive: Composed of hypertensive women who participated in a training program with Pilates exercises in the soil associated to the daily antihypertensive of each one. * Group 2 - Normotensives: Composed of normotensive women who participated in a training program with solo Pilates exercises without antihypertensive presence. Both groups underwent 12 weeks of Pilates training.
Eligibility
Sex/Gender
FEMALE
Age
40 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Women between the ages of 40 and 70; * Be post menopausal (amenorrhea for at least 12 months); * Medical release to perform physical activities. * Do not present physical problems or cardiovascular complications that prevent the performance of physical exercises;
Exclusion criteria
* To present a history of stroke or acute myocardial infarction; * Smoking; * Diagnosis of Diabetes Mellitus. * Present renal pathologies. * Use medications that interfere with lipid metabolism; * Use of antihypertensive drugs (except for the hypertensive group); * Use hormone replacement therapies; * Present gastrointestinal conditions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Blood pressure | Change from Baseline at 12 weeks | Resting diastolic and systolic blood pressures will be monitored by Microlife® BP 3BT0A automatic monitor in mmHg. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Ambulatory blood pressure monitoring | Change from Baseline at 12 weeks | Ambulatory blood pressure monitoring will be monitored during 24 hours using a Dyna+ ABPM device in mmHg. |
| Kupperman - Blatt Index | Change from Baseline at 12 weeks | The climacteric symptoms will be evaluated by the following questionnaire Kupperman - Blatt Index. The questionnaire has scores that from 0 to 19 indicate mild symptoms, 20 to 35 moderate and greater than 35 symptoms of severe climacteric. |
| Menopause Rating Scale (MRS) | Change from Baseline at 12 weeks | The climacteric symptoms will be evaluated by the following questionnaire Menopause Rating Scale (MRS). The scores from 0 to 4 of the questionnaire indicate absence of symptoms, as well as from 5 to 8 presence of mild symptoms, 9 to 15 moderate and greater than 16 symptoms of severe climacteric. |
| Sleep quality | Change from Baseline at 12 weeks | Sleep quality will be assessed by the Pittsburgh Sleep Quality Index (PSQI).A score of 0 to 4 indicates a good quality of sleep, 5 to 10 quality of bad sleep and greater than 10 the presence of sleep disorder. |
| Cervical Scale | Change from Baseline at 12 weeks | The climacteric symptoms will be evaluated by the following questionnaire Cervical Scale. The questionnaire does not have scales. Indicates only a high or low score regarding the presence of climacteric symptoms. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Biochemical analyzes | Change from Baseline at 12 weeks | From the serum and/or plasma and saliva samples collected and stored, analyzes for lipid profile (total cholesterol and fractions, and triglycerides) and glycemia at rest and for the concentrations of inflammatory cytokines and changes in the activity of the Antioxidant system. |
Countries
Brazil
Outcome results
None listed